Luseogliflozin Suppresses Late-Night Basal Glycemic Variability in Type 2 Diabetes: A Retrospective Observational Study

This is the first study to demonstrate that an SGLT2 inhibitor can suppress nocturnal basal GV immediately after initiation. Given that GV has been associated with sympathetic activation and vascular injury, these results suggest that reducing basal GV with SGLT2 inhibitors may contribute to vascular protection. Further studies with larger sample sizes and longer follow-up are warranted to confirm these observations.